尊龙凯时·(中国)人生就是搏!

Essex-Bio Group

簡繁 EN

COMPANY NEWS

Essex Bio-Technology (1061.HK) 2023 Annual Results at a glance

2024.03.19

Essex Bio-Technology Posts Sound 2023 Annual Financial Results: Revenue Up 29.5%, Profit Up 22.1%

2024.03.18

Change of Address of Head Office and Principal Place of Business in Hong Kong

2024.01.03

Date

Title

2024-03-19

Essex Bio-Technology (1061.HK) 2023 Annual Results at a glance

2024-03-18

Essex Bio-Technology Posts Sound 2023 Annual Financial Results: Revenue Up 29.5%, Profit Up 22.1%

2024-01-03

Change of Address of Head Office and Principal Place of Business in Hong Kong

2023-08-16

Essex Bio-Technology (1061.HK) 2023 Interim Results at a glance

2023-08-16

Essex Bio-Technology Posts Sound 2023 Interim Financial Results Revenue Up 37.1%, Profit Up 22%

2023-07-26

The phase 1/2 clinical trial of Bevacizumab for treatment of Ophthalmic Diseases completed

2023-06-30

EssexBio awarded 「2022 China Pharmaceutical Industry Top 100 Series List」 and 「2023 China Pharmaceutical Brands List」

2023-04-14

Essex and Osteopore Entered into Exclusive Distribution Agreement for Oral Maxillofacial products in Singapore

Essex-Bio Group

BIOTECH

HEALTHTECH

Links

Wuhan Adv.Dental Bio-Technology

UNO Medical Group

Antikor Biopharma

Mitotech S.A.

Henlius

Humacyte

Copyright © 2020 Essex Bio-Technology Limited All Rights Reserved.
Disclaimer | Privacy Policy

粵公網安備 44049102496184號粵ICP備09032349號-1
互聯網藥品信息服務資格證書編號:（粵）-非經營性-2019-0118 深圳網站建設深圳聯雅

This website uses cookies to improve your overall experience. With your continued use, you are agreeing to accept our use of cookies.

ACCEPT